Serious adverse events · people with asthma
Reslizumab intravenous (IV) showed no clear difference in serious adverse events compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events · people with asthma
Reslizumab subcutaneous (SC) showed no clear difference in serious adverse events compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events · people with asthma
Benralizumab subcutaneous (SC) leads to lower serious adverse events compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events · people with asthma
Mepolizumab subcutaneous (SC) showed no clear difference in serious adverse events compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events · people with systemic sclerosis
Autologous myeloablative selective HSCT showed no clear difference in serious adverse events compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Serious adverse events · people with systemic sclerosis
1 finding from 1 review
Serious adverse events · people with systemic sclerosis
Autologous non‐myeloablative selective HSCT probably leads to higher serious adverse events compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Serious adverse events · people with substance use disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with substance use disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Serious adverse events
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Serious adverse events
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · Induction of Remission in Medically Refractory Crohn's Disease
Summary of findings table ‐ Stem Cell showed no clear difference in serious Adverse Events compared with placebo or Control (low certainty).
1 finding from 1 review
Serious adverse events · people with bronchiectasis
28 days on/off antibiotic regimen showed no clear difference in serious adverse events compared with 28 days on/off placebo regimen (low certainty).
1 finding from 1 review
OR 1 [0.68, 1.46]
Studies not reported
Low
Serious adverse events · people with bronchiectasis
14 days on/off antibiotic regimen showed no clear difference in serious adverse events compared with 28 days on/off antibiotic regimen (moderate certainty).
1 finding from 1 review
OR 0.83 [0.37, 1.86]
Studies not reported
Moderate
Serious adverse events · people with bronchiectasis
14 days on/off antibiotic regimen showed no clear difference in serious adverse events compared with 14 days on/off placebo regimen (high certainty).
1 finding from 1 review
OR 0.92 [0.63, 1.33]
Studies not reported
High
Serious adverse events · children with Hirschsprung's disease (HD)
1 finding from 1 review
Serious adverse events · people with active UC
1 finding from 1 review
Serious adverse events · people with active UC
1 finding from 1 review